Floatz Rating
C39/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
antibody_drug_conjugate
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03816358CT.gov Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anetumab Ravtansine (this asset) | National Cancer Institute (NCI) | P1 | C · 39 |
| Fluorouracilum | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Irinotecan | Jonsson Comprehensive Cancer Center | P3 | BB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| Docetaxel | Bristol-Myers Squibb | P2 | BB |
| Olaparib | Lantern Pharma Inc. | P3 | BB |
| Capecitabine | Zhejiang University | P4 | BB |
| Irinotecan Sucrosofate | SWOG Cancer Research Network | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Jonsson Comprehensive Cancer Center | P2/3 | B |
+42 more in the Pancreatic Adenocarcinoma cohort
Other indications for Anetumab Ravtansine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Fallopian Tube Serous Adenocarcinoma | — | P2 | CCC · 52 |
| Primary Peritoneal Serous Adenocarcinoma | — | P2 | CCC · 52 |
| Ovarian Serous Adenocarcinoma | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anetumab Ravtansine in Pancreatic Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anetumab-ravtansine-pancreatic-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →